Clinical Trial: A Phase I Study of HRS-7172 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications

U.S., Aug. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07142980) titled 'A Phase I Study of HRS-7172 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications' on Aug. 20.

Brief Summary: This is a phase I study of HRS-7172 to evaluate safety, tolerability and pharmacokinetics in participants with advanced solid tumors harboring RAS mutations or amplifications.

Study Start Date: Sept., 2025

Study Type: INTERVENTIONAL

Condition: Advanced Solid Tumors Harboring RAS Mutations or Amplifications

Intervention: DRUG: HRS-7172 Tablets

HRS-7172 tablets.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Disclaimer: Curated by HT Syndication....